Objective To measure the effectiveness of the quadrivalent human papillomavirus (HPV)
vaccine against cervical abnormalities four years after implementation of a nationally funded …

Objective To quantify the effect on cervical disease at age 20 years of immunisation with
bivalent human papillomavirus (HPV) vaccine at age 12-13 years. Design Retrospective …

Objective To review the first two years of the primary human papillomavirus (HPV) cervical
screening programme in an HPV vaccinated population. Design Observational study …

Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

Summary Background On Sept 1, 2008, Scotland launched routine vaccination for human
papillomavirus (HPV) types 16 and 18, targeted at 12–13-year-old girls, of whom 92· 4 …

Background Australia was one of the first countries to introduce a publicly funded national
human papillomavirus (HPV) vaccination program that commenced in April 2007, using the …

Background Australia introduced a human papillomavirus (HPV) vaccination programme
with the quadrivalent HPV vaccine for all women aged 12–26 years between 2007 and …

Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …

Aim Prophylactic human papillomavirus (HPV) vaccines are highly effective at preventing
pre–cancerous cervical lesions when given in a three–dose schedule. Some post–hoc trial …

Objective To assess the feasibility and acceptability of delivering a human papillomavirus
(HPV) vaccine to adolescent girls. Design Prospective cohort study. Setting 36 secondary …